Recently, it has been demonstrated that administration of anti-CD47 antibodies significantly enhanced trastuzumab-mediated ADCP and improved antitumor responses and may help to resensitize refractory HER2+ breast cancers to trastuzumab treatment [224]. The gene discussed is ERBB2; the disease is breast cancer.